ArticleDiscover oncology2025
Metastatic patterns and survival outcomes across molecular subtypes in a large cohort of breast cancer patients from the Shiraz breast cancer registry.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Site-Specific Patterns of Distant Relapse on ^18F-FDG PET/Contrast-Enhanced CT According to Molecular Subtype in Breast Cancer: A Retrospective Cohort Study.Nuclear medicine and molecular imaging · 2026Article
- Review
- Independent Risk Factors and a New Nomogram for Predicting Breast Cancer Risk for Bone Metastasis in Chinese Women: A Retrospective Study with External Validation.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeBreast cancer molecular subtypes significantly influence metastatic behavior and survival outcomes. However, data on subtype-specific patterns of distant metastasis and prognosis in Middle Eastern populations remain scarce. This study addresses this gap by analyzing a large cohort from southern Iran to better characterize these differences and aid personalized treatment.
methodsIn this study, 8,491 women with breast cancer from the Shiraz Breast Cancer Registry were analyzed. Patients had known molecular subtypes based on estrogen receptor, progesterone receptor, and HER2 status, and no distant metastases at diagnosis. Patients were followed up until December 30, 2024. Kaplan-Meier, restricted mean survival time and Cox proportional hazards models assessed overall survival (OS) and distant metastasis-free survival (DMFS). (SPSSv27.0 & R package RMST2)
resultsLuminal A (58.7%) was the most common subtype, followed by Luminal B (18.0%), Triple-Negative (12.7%), and HER2-enriched (10.6%). Among 1,304 patients who developed metastases, Luminal subtypes predominantly showed bone metastasis, whereas Triple-Negative and HER2-enriched tumors favored lung metastasis. Five-year OS differed significantly (p = 0.002), highest in Luminal A (85.1%) and lowest in HER2-enriched (74.2%). Cox regression revealed increased mortality risks for HER2-enriched (HR = 1.83), Triple-Negative (HR = 1.78), and Luminal B (HR = 1.24) compared to Luminal A. DMFS also favored Luminal A.
conclusionThis study fills an important regional research gap by demonstrating distinct distant metastasis patterns and survival outcomes across breast cancer molecular subtypes in southern Iran. Luminal A patients have the best prognosis, while HER2-enriched and Triple-Negative subtypes are more aggressive. These findings reinforce the prognostic and therapeutic value of subtype classification in guiding personalized breast cancer management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.